138P Results of the NOGGO PERCEPTION: Phase II investigational study of pembrolizumab in combination with chemotherapy in platinum-sensitive recurrent low-grade serous ovarian cancer

Low-grade serous ovarian cancer (LGSOC) is a rare malignancy with limited responsiveness to chemotherapy, highlighting the urgent need for novel therapeutic strategies to improve treatment outcomes. Immune checkpoint inhibitors, such as pembrolizumab, have demonstrated efficacy in various cancers, including certain ovarian cancer subtypes, and could represent a promising treatment option for LGSOC.

Authors

Institutions

Publication Details

Journal
ESMO Open
Published
2026-07-01
DOI
https://doi.org/10.1016/j.esmoop.2026.108185
Primary Topic
Ovarian cancer diagnosis and treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

138P Results of the NOGGO PERCEPTION: Phase II investigational study of pembrolizumab in combination with chemotherapy in platinum-sensitive recurrent low-grade serous ovarian cancer

D. Zocholl, F. Heitz, J. Sehouli, J. Welz et al.
ESMO Open
Ovarian cancer diagnosis and treatment
article

138P Results of the NOGGO PERCEPTION: Phase II investigational study of pembrolizumab in combination with chemotherapy in platinum-sensitive recurrent low-grade serous ovarian cancer

D. Zocholl, F. Heitz, J. Sehouli, J. Welz, E.I. Braicu, J.P. Grabowski, P. Harter, F. Schmeling, T. Arndt
article en

Abstract

Low-grade serous ovarian cancer (LGSOC) is a rare malignancy with limited responsiveness to chemotherapy, highlighting the urgent need for novel therapeutic strategies to improve treatment outcomes. Immune checkpoint inhibitors, such as pembrolizumab, have demonstrated efficacy in various cancers, including certain ovarian cancer subtypes, and could represent a promising treatment option for LGSOC.

ESMO OpenVol. 11
Berlin Institute of Health at Charité - Universitätsmedizin Berlin (DE), Kliniken Essen-Mitte (DE), Nord-Ostdeutsche Gesellschaft für Gynäkologische Onkologie (DE), Charité - Universitätsmedizin Berlin (DE)
Good health and well-being
Openalex Percentile: Top 6%
Ovarian cancer diagnosis and treatment
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

138P Results of the NOGGO PERCEPTION: Phase II investigational study of pembrolizumab in combination with chemotherapy in platinum-sensitive recurrent low-grade serous ovarian cancer — D. Zocholl, F. Heitz, et al. · ESMO Open (2026) | TGRS Research Map | TGRS